title: Drug safety evaluation of  pregabalin.
abstract: BACKGROUND
  Pregabalin is an anticonvulsant with one known mechanism of action which is used most specifically in the management of neuropathic pain.
  
  
  METHODS
  The adverse effect profile of this medication from controlled, randomized studies as well as open and long-term studies is described with consideration of the evidence-based results for pregabalin's clinical use.
  
  
  CONCLUSIONS
  Pregabalin is a mostly well tolerated medication for the management of neuropathic pain and other conditions. Pregabalin use is associated with benign central nervous system and systemic adverse effects with very limited metabolic, idiosyncratic, or teratogenic adverse effects. Understanding of these adverse effects is essential for the clinician treating the patient and for the patient receiving treatment. Sedation, dizziness, peripheral edema, and dry mouth are the most prevalent adverse events experienced in all clinical populations. Other adverse effects are rare, but are discussed.
authors.affiliation: University of Calgary, Department of Clinical Neurosciences, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada. corytoth@shaw.ca
authors.forename: Cory
authors.initials: C
authors.lastname: Toth
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D061214:Patient Safety; D000069583:Pregabalin; D018570:Risk Assessment; D012307:Risk Factors; D012640:Seizures / Q000517:prevention & control*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid